The safety and tolerability of a mixed lineage kinase inhibitor (CEP-1347) in PD.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 14745084.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
CEP-1347 is an inhibitor of members of the mixed lineage kinase family, key signals triggering apoptotic neuronal death. The authors performed a randomized, blinded, placebo-controlled study assessing the safety, tolerability, pharmacokinetics, and acute symptomatic effects of CEP-1347 in 30 patients with Parkinson's disease (PD). In this short-term study, CEP-1347 was safe and well tolerated. It had no acute effect on parkinsonian symptoms or levodopa pharmacokinetics, making it well suited for larger and longer studies of its potential to modify the course of PD.
Medical subject headings
- Antiparkinson Agents
- Carbazoles
- Indoles
- Parkinson Disease
- Protein Kinase Inhibitors